Class: Topical Corticosteroid
Dosage Forms. Cream: 0.05%; Ointment: 0.05%; Topical Solution: 0.05%; Aerosol Foam: 0.05%; Gel: 0.05%; Shampoo: 0.05%
Common FDA Label Indication, Dosing, and Titration.
1. Skin disorders, corticosteroid responsive: Children 12 y and older and Adults, apply thin layer topically to affected area bid for a max of 2 wk
2. Plaque psoriasis: Children 12 y and older and adults, apply thin layer topically to affected area bid for a max of 2-4 wk
1. Oral lichen planus: Apply thin layer topically bid with antimycotics
MOA. Clobetasol has anti-inflammatory, antipruritic, and vasoconstrictive properties. Corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.
Drug Characteristics: Clobetasol
Medication Safety Issues: Clobetasol
Drug Interactions: Clobetasol. None known
Adverse Reactions: Clobetasol
Efficacy Monitoring Parameters. Improvement in clinical signs of skin disorder.
Toxicity Monitoring Parameters. Seek medical attention if severe skin irritation or symptoms worsen after administration.
Key Patient Counseling Points. Apply thin layer to affected area of skin. Skin should be clean and intact at site of application. Avoid contact with eyes and do not ingest by mouth. Avoid occlusive dressings or tight-fitting clothes over site of administration.
Clinical Pearls. Various dosage forms (foams, gels, shampoos, etc) also available. Very high potency corticosteroid. Application to large surface areas, prolonged use, and occlusive dressings may increase risk of systemic absorption and toxicity. Pediatric patients are more susceptible to systemic absorption.